CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
about
HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinomaEnrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosisCancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells.GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2.Involvement of microRNAs in HER2 signaling and trastuzumab treatment.CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.Functional miRNAs in breast cancer drug resistance.An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancerPrediction of key genes and pathways involved in trastuzumab-resistant gastric cancerA correlation study of the expression of HA-CD44st and HER-2 in breast cancer
P2860
Q33626569-C49E8F24-448A-407A-8ED8-F737BD0A6A61Q36261757-EB888835-A3FD-4046-92CF-BD182D9D1C98Q36504123-00020AF4-2E84-4587-A427-05F183B06310Q36544839-BE1B8E87-1241-4E5C-BD40-F0FC302566CAQ36545717-08987874-5504-405C-9A9A-18A181C7D8CEQ36962950-300F908B-438D-4321-9E58-B74A90686B1BQ37709365-CC4728E5-4B16-4580-AB04-5D81A9AE04D4Q38695440-0FD2DB2A-4B8D-4871-A99F-14A19130D8C5Q38719786-4DBBA87A-1CB8-4153-8EE2-E8E31209B437Q38795514-CED2E06B-013A-413A-9E95-8B17E38A1A28Q38979308-5A74D836-480A-4A06-BDFC-0C0520321CC3Q48053117-D20DD65E-28CF-4DF2-9E2D-4CA296B369E1Q55000578-1B1E6B7F-FE54-478A-958D-21954CAB1302Q56530979-07ADBFA6-1C5C-46BB-9B12-F665EB0616B0Q58720903-547C9679-41FA-405E-A2D6-E9E111B4B469Q58754066-047EC362-19A9-4F6A-B95F-4592AE2C2EAC
P2860
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CD44 expression contributes to ...... -positive breast cancer cells.
@en
type
label
CD44 expression contributes to ...... -positive breast cancer cells.
@en
prefLabel
CD44 expression contributes to ...... -positive breast cancer cells.
@en
P2093
P2860
P1476
CD44 expression contributes to ...... 2-positive breast cancer cells
@en
P2093
Chandra Bartholomeusz
Delphine R Boulbes
Gaurav B Chauhan
Quanri Jin
P2860
P2888
P304
P356
10.1007/S10549-015-3414-3
P407
P577
2015-05-14T00:00:00Z
P6179
1005107265